10/31/2014 - 11:08am

Novo Nordisk announced the launch of NovoFine Plus in the United States. NovoFine Plus is a universal needle that works with all currently available insulin, as well as some GLP-1 receptor agonist pens, the company said. 

 

10/31/2014 - 10:35am

Mylan on Friday announced the launch of nevirapine extended-release tablets in 400-mg strength, a generic version of Viramune XR from Boehringer Ingelheim. 

10/30/2014 - 12:54pm

AstraZeneca on Thursday announced that the Food and Drug Administration approved Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily drug for the treatment of adults with Type 2 diabetes. 

10/30/2014 - 11:44am

Dr. Reddy's Labs on Tuesday announced the launch of sirolimus tablets in 1-mg and 2-mg dosage strengths.

10/21/2014 - 12:35pm

Boehringer Ingelheim Pharmaceuticals on Monday announced that Ofev (nintedanib) capsules are now available in the United States. Ofev was approved by the Food and Drug Administration on Oct. 15 to treat idiopathic pulmonary fibrosis.

10/16/2014 - 11:52am

The Food and Drug Administration has granted approval to Esbriet (pirfenidone), as well as Ofev (nintedanib), to treat idiopathic pulmonary fibrosis — a condition in which the lungs scar over time.

10/13/2014 - 1:15pm

Church & Dwight on Monday announced the launch of Replens Silky Smooth.

10/10/2014 - 1:22pm

The Food and Drug Administration on Friday approved Akynzeo (netupitant and palonosetron) for the treatment of nausea and vomiting in patients who are undergoing cancer chemotherapy.

10/09/2014 - 2:49pm

Purdue Pharma on Thursday announced the launch of a new dosage strength of 7.5 mcg/hour for its Butrans (buprenorphine) transdermal system CIII, bringing the total number of strengths offered by the company to five.